Qsymia (Phentermine-Topiramate) Market Forecast for Obesity Treatment to 2032
ResearchAndMarkets.com has released a report analyzing the market and forecast for Qsymia (phentermine-topiramate) drug for obesity treatment through 2032 across key markets.
A new report from ResearchAndMarkets.com provides a comprehensive analysis of the Qsymia (phentermine-topiramate) drug market and its future projections for obesity treatment up to 2032. The study covers major markets, including the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Qsymia, previously known as Qnexa, is a combination of phentermine, an anorectic agent, and topiramate extended-release, an antiepileptic drug. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. It is indicated for individuals with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) when accompanied by at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
The report delves into Qsymia's mechanism of action, dosage, and administration. It also details the drug's research and development activities, including regulatory milestones and other developmental progress. The analysis includes future market assessments, a SWOT analysis, expert opinions from analysts, and an overview of the competitive landscape and emerging therapies in the obesity treatment sector.
This report is intended to offer crucial insights for pharmaceutical companies, healthcare professionals, and investors tracking the evolving market for obesity management drugs. It aims to present a clear understanding of Qsymia's current standing and future potential in the global pharmaceutical market.